array(40) {
  [0]=>
  string(4) "2009"
  ["article_id"]=>
  string(4) "2009"
  [1]=>
  string(176) "Avanir Pharmaceuticals, Inc. Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia"
  ["article_title"]=>
  string(176) "Avanir Pharmaceuticals, Inc. Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia"
  [2]=>
  string(150) "ALISO VIEJO, Calif., March 25, 2019 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. announced today the results from the first study of the company's"
  ["short_description"]=>
  string(150) "ALISO VIEJO, Calif., March 25, 2019 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. announced today the results from the first study of the company's"
  [3]=>
  string(245) "ALISO VIEJO, Calif., March 25, 2019 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. announced today the results from the first study of the company's phase 3 clinical development program investigating the efficacy, safety and tolerability of..."
  ["description"]=>
  string(245) "ALISO VIEJO, Calif., March 25, 2019 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. announced today the results from the first study of the company's phase 3 clinical development program investigating the efficacy, safety and tolerability of..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/avanir-pharmaceuticals-inc-reports-phase-3-data-evaluating-investigational-avp-786-moderate-severe-18117.html?utm_source=ddc&utm_medium=rss&utm_campaign=Avanir+Pharmaceuticals%2C+Inc.+Reports+Phase+3+Data+Evaluating+Investigational+AVP-786+for+the+Treatment+of+M"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/avanir-pharmaceuticals-inc-reports-phase-3-data-evaluating-investigational-avp-786-moderate-severe-18117.html?utm_source=ddc&utm_medium=rss&utm_campaign=Avanir+Pharmaceuticals%2C+Inc.+Reports+Phase+3+Data+Evaluating+Investigational+AVP-786+for+the+Treatment+of+M"
  [15]=>
  string(19) "2019-03-25 15:04:47"
  ["add_date"]=>
  string(19) "2019-03-25 15:04:47"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4521"
  ["article_id"]=>
  string(4) "4521"
  [1]=>
  string(60) "3rd International Conference on Women Health & Breast Cancer"
  ["article_title"]=>
  string(60) "3rd International Conference on Women Health & Breast Cancer"
  [2]=>
  string(155) "It’s time to take care of you. So, on behalf of Euroscicon we are glad and privileged to invite you to join the 3rd International Conference onWomen"
  ["short_description"]=>
  string(155) "It’s time to take care of you. So, on behalf of Euroscicon we are glad and privileged to invite you to join the 3rd International Conference onWomen"
  [3]=>
  string(510) "It’s time to take care of you. So, on behalf of Euroscicon we are glad and privileged to invite you to join the 3rd International Conference onWomen Health and Breast Cancer which is going to be held in Dubai, UAE on September 26-27, 2019.&#nlThe theme of the conference is aiming to promote quality research and real-world impact in an atmosphere of true international cooperation between scientists by bringing together again the world class researchers, International Communities and Industrial he..."
  ["description"]=>
  string(510) "It’s time to take care of you. So, on behalf of Euroscicon we are glad and privileged to invite you to join the 3rd International Conference onWomen Health and Breast Cancer which is going to be held in Dubai, UAE on September 26-27, 2019.&#nlThe theme of the conference is aiming to promote quality research and real-world impact in an atmosphere of true international cooperation between scientists by bringing together again the world class researchers, International Communities and Industrial he..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(90) "https://www.pharmiweb.com/event/3rd-international-conference-on-women-health-breast-cancer"
  ["blog_url"]=>
  string(90) "https://www.pharmiweb.com/event/3rd-international-conference-on-women-health-breast-cancer"
  [15]=>
  string(19) "2019-03-23 14:26:19"
  ["add_date"]=>
  string(19) "2019-03-23 14:26:19"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1771"
  ["article_id"]=>
  string(4) "1771"
  [1]=>
  string(54) "Changing attitudes for biosimilars in gastroenterology"
  ["article_title"]=>
  string(54) "Changing attitudes for biosimilars in gastroenterology"
  [2]=>
  string(152) "Professor Tibor Hlavatý, from United European Gastroenterology, which is a European umbrella organisation for gastroenterologists, gave a presentatio"
  ["short_description"]=>
  string(152) "Professor Tibor Hlavatý, from United European Gastroenterology, which is a European umbrella organisation for gastroenterologists, gave a presentatio"
  [3]=>
  string(376) "
Professor Tibor Hlavatý, from United European Gastroenterology, which is a European umbrella organisation for gastroenterologists, gave a presentation on the current position of biosimilars in the field of gastroenterology at the fourth European Commission Stakeholder Conference on Biosimilar Medicines, which was held on 14 September 2018 in Brussels, Belgium [1].
"
  ["description"]=>
  string(376) "
Professor Tibor Hlavatý, from United European Gastroenterology, which is a European umbrella organisation for gastroenterologists, gave a presentation on the current position of biosimilars in the field of gastroenterology at the fourth European Commission Stakeholder Conference on Biosimilar Medicines, which was held on 14 September 2018 in Brussels, Belgium [1].
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(89) "http://www.gabionline.net//Reports/Changing-attitudes-for-biosimilars-in-gastroenterology"
  ["blog_url"]=>
  string(89) "http://www.gabionline.net//Reports/Changing-attitudes-for-biosimilars-in-gastroenterology"
  [15]=>
  string(19) "2019-03-22 18:56:22"
  ["add_date"]=>
  string(19) "2019-03-22 18:56:22"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-03-25 16:03:40"
  ["create_at"]=>
  string(19) "2019-03-25 16:03:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1772"
  ["article_id"]=>
  string(4) "1772"
  [1]=>
  string(45) "FDA approves trastuzumab biosimilar Trazimera"
  ["article_title"]=>
  string(45) "FDA approves trastuzumab biosimilar Trazimera"
  [2]=>
  string(155) "Pharma giant Pfizer announced on 11 March 2019 that the US Food and Drug Administration (FDA) had approved its biosimilar version of Roche’s Hercept"
  ["short_description"]=>
  string(155) "Pharma giant Pfizer announced on 11 March 2019 that the US Food and Drug Administration (FDA) had approved its biosimilar version of Roche’s Hercept"
  [3]=>
  string(179) "
Pharma giant Pfizer announced on 11 March 2019 that the US Food and Drug Administration (FDA) had approved its biosimilar version of Roche’s Herceptin (trastuzumab).
"
  ["description"]=>
  string(179) "
Pharma giant Pfizer announced on 11 March 2019 that the US Food and Drug Administration (FDA) had approved its biosimilar version of Roche’s Herceptin (trastuzumab).
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(89) "http://www.gabionline.net//Biosimilars/News/FDA-approves-trastuzumab-biosimilar-Trazimera"
  ["blog_url"]=>
  string(89) "http://www.gabionline.net//Biosimilars/News/FDA-approves-trastuzumab-biosimilar-Trazimera"
  [15]=>
  string(19) "2019-03-22 18:39:41"
  ["add_date"]=>
  string(19) "2019-03-22 18:39:41"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-03-25 16:03:40"
  ["create_at"]=>
  string(19) "2019-03-25 16:03:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1773"
  ["article_id"]=>
  string(4) "1773"
  [1]=>
  string(62) "Clinician biosimilar prescribing habits and need for education"
  ["article_title"]=>
  string(62) "Clinician biosimilar prescribing habits and need for education"
  [2]=>
  string(150) "At present, biosimilar prescribing and clinical use remain contingent on individual healthcare provider preferences. Although novel legislation and po"
  ["short_description"]=>
  string(150) "At present, biosimilar prescribing and clinical use remain contingent on individual healthcare provider preferences. Although novel legislation and po"
  [3]=>
  string(554) "
At present, biosimilar prescribing and clinical use remain contingent on individual healthcare provider preferences. Although novel legislation and policy continue to promote biosimilar drug development, clinician hesitancies curtail biosimilar use in practice, thereby limiting overall market uptake. Findings from a recently published systematic review indicate that clinicians in Europe and the US do not primarily support the use of biosimilars as safe and effective therapies in patients already receiving originator biological treatment [1].
"
  ["description"]=>
  string(554) "
At present, biosimilar prescribing and clinical use remain contingent on individual healthcare provider preferences. Although novel legislation and policy continue to promote biosimilar drug development, clinician hesitancies curtail biosimilar use in practice, thereby limiting overall market uptake. Findings from a recently published systematic review indicate that clinicians in Europe and the US do not primarily support the use of biosimilars as safe and effective therapies in patients already receiving originator biological treatment [1].
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(110) "http://www.gabionline.net//Biosimilars/Research/Clinician-biosimilar-prescribing-habits-and-need-for-education"
  ["blog_url"]=>
  string(110) "http://www.gabionline.net//Biosimilars/Research/Clinician-biosimilar-prescribing-habits-and-need-for-education"
  [15]=>
  string(19) "2019-03-22 18:27:06"
  ["add_date"]=>
  string(19) "2019-03-22 18:27:06"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-03-25 16:03:40"
  ["create_at"]=>
  string(19) "2019-03-25 16:03:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1774"
  ["article_id"]=>
  string(4) "1774"
  [1]=>
  string(64) "Fujifilm acquires Biogen Hillerød facility for US$890 million"
  ["article_title"]=>
  string(64) "Fujifilm acquires Biogen Hillerød facility for US$890 million"
  [2]=>
  string(150) "On 12 March 2019, Biogen announced that it had entered into an agreement with Fujifilm Corporation under which Fujifilm will acquire Biogen Manufactur"
  ["short_description"]=>
  string(150) "On 12 March 2019, Biogen announced that it had entered into an agreement with Fujifilm Corporation under which Fujifilm will acquire Biogen Manufactur"
  [3]=>
  string(676) "
On 12 March 2019, Biogen announced that it had entered into an agreement with Fujifilm Corporation under which Fujifilm will acquire Biogen Manufacturing ApS from Biogen for up to US$890 million in cash. Biogen Manufacturing ApS is a large-scale biologicals manufacturing site located in Hillerød, Denmark (Biogen Hillerød). Biogen Hillerød will become Fujifilm's fourth biopharmaceutical contract development and manufacturing site upon closure of this transaction, which is expected in August 2019 subject to closing conditions. The existing workforce at the site, consisting of approximately 800 employees, will continue employment under Fujifilm. 
"
  ["description"]=>
  string(676) "
On 12 March 2019, Biogen announced that it had entered into an agreement with Fujifilm Corporation under which Fujifilm will acquire Biogen Manufacturing ApS from Biogen for up to US$890 million in cash. Biogen Manufacturing ApS is a large-scale biologicals manufacturing site located in Hillerød, Denmark (Biogen Hillerød). Biogen Hillerød will become Fujifilm's fourth biopharmaceutical contract development and manufacturing site upon closure of this transaction, which is expected in August 2019 subject to closing conditions. The existing workforce at the site, consisting of approximately 800 employees, will continue employment under Fujifilm. 
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(101) "http://www.gabionline.net//Pharma-News/Fujifilm-acquires-Biogen-Hilleroed-facility-for-US-890-million"
  ["blog_url"]=>
  string(101) "http://www.gabionline.net//Pharma-News/Fujifilm-acquires-Biogen-Hilleroed-facility-for-US-890-million"
  [15]=>
  string(19) "2019-03-22 18:03:02"
  ["add_date"]=>
  string(19) "2019-03-22 18:03:02"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-03-25 16:03:40"
  ["create_at"]=>
  string(19) "2019-03-25 16:03:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5317"
  ["article_id"]=>
  string(4) "5317"
  [1]=>
  string(20) "Benelux ePharma Day "
  ["article_title"]=>
  string(20) "Benelux ePharma Day "
  [2]=>
  string(156) "The future is now: challenges and opportunities in clinical research in Benelux&#nlThe way how Clinical Trials are run is entering extraordinary times.&#nlE"
  ["short_description"]=>
  string(156) "The future is now: challenges and opportunities in clinical research in Benelux&#nlThe way how Clinical Trials are run is entering extraordinary times.&#nlE"
  [3]=>
  string(509) "The future is now: challenges and opportunities in clinical research in Benelux&#nlThe way how Clinical Trials are run is entering extraordinary times.&#nlEvolutions in technology, regulations and processes bring along unprecedented challenges and opportunities for all parties involved. For the patients and their caregiver, the sites, the health care professional, the regulator, the sponsor, the vendors and CROs.&#nlDuring the Benelux ePharma Day we bring all stakeholders together and will have discus..."
  ["description"]=>
  string(509) "The future is now: challenges and opportunities in clinical research in Benelux&#nlThe way how Clinical Trials are run is entering extraordinary times.&#nlEvolutions in technology, regulations and processes bring along unprecedented challenges and opportunities for all parties involved. For the patients and their caregiver, the sites, the health care professional, the regulator, the sponsor, the vendors and CROs.&#nlDuring the Benelux ePharma Day we bring all stakeholders together and will have discus..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(51) "https://www.pharmiweb.com/event/benelux-epharma-day"
  ["blog_url"]=>
  string(51) "https://www.pharmiweb.com/event/benelux-epharma-day"
  [15]=>
  string(19) "2019-03-22 18:00:06"
  ["add_date"]=>
  string(19) "2019-03-22 18:00:06"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:28"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1775"
  ["article_id"]=>
  string(4) "1775"
  [1]=>
  string(103) "Factors associated with increased side effects and lower perceived efficacy when switching to a generic"
  ["article_title"]=>
  string(103) "Factors associated with increased side effects and lower perceived efficacy when switching to a generic"
  [2]=>
  string(150) "In 2017, the New Zealand Pharmaceutical Management Agency (PHARMAC) changed the funded version of the antidepressant venlafaxine from Efexor XR (the b"
  ["short_description"]=>
  string(150) "In 2017, the New Zealand Pharmaceutical Management Agency (PHARMAC) changed the funded version of the antidepressant venlafaxine from Efexor XR (the b"
  [3]=>
  string(637) "
In 2017, the New Zealand Pharmaceutical Management Agency (PHARMAC) changed the funded version of the antidepressant venlafaxine from Efexor XR (the branded originator) or Arrow-Venlafaxine XR (a generic version) to a new generic, Enlafax XR. MacKrill and Petrie examined differences in preferences and perceptions between patients switched from the originator branded venlafaxine to the new generic, and those switched from the old generic version [1]. Specifically, they investigated the factors associated with preference for branded medicines, side effects reported following switching and efficacy ratings of the new generic.
"
  ["description"]=>
  string(637) "
In 2017, the New Zealand Pharmaceutical Management Agency (PHARMAC) changed the funded version of the antidepressant venlafaxine from Efexor XR (the branded originator) or Arrow-Venlafaxine XR (a generic version) to a new generic, Enlafax XR. MacKrill and Petrie examined differences in preferences and perceptions between patients switched from the originator branded venlafaxine to the new generic, and those switched from the old generic version [1]. Specifically, they investigated the factors associated with preference for branded medicines, side effects reported following switching and efficacy ratings of the new generic.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(148) "http://www.gabionline.net//Generics/Research/Factors-associated-with-increased-side-effects-and-lower-perceived-efficacy-when-switching-to-a-generic"
  ["blog_url"]=>
  string(148) "http://www.gabionline.net//Generics/Research/Factors-associated-with-increased-side-effects-and-lower-perceived-efficacy-when-switching-to-a-generic"
  [15]=>
  string(19) "2019-03-22 17:48:09"
  ["add_date"]=>
  string(19) "2019-03-22 17:48:09"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-03-25 16:03:40"
  ["create_at"]=>
  string(19) "2019-03-25 16:03:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1776"
  ["article_id"]=>
  string(4) "1776"
  [1]=>
  string(87) "Celltrion wins biosimilar deals and Duopharma increases focus on biosimilars in SE Asia"
  ["article_title"]=>
  string(87) "Celltrion wins biosimilar deals and Duopharma increases focus on biosimilars in SE Asia"
  [2]=>
  string(150) "Celltrion Healthcare (Celltrion) has won tenders to supply infliximab to Singapore and rituximab to Thailand, while CCM Duopharma Biotech Bhd (CCMD) a"
  ["short_description"]=>
  string(150) "Celltrion Healthcare (Celltrion) has won tenders to supply infliximab to Singapore and rituximab to Thailand, while CCM Duopharma Biotech Bhd (CCMD) a"
  [3]=>
  string(244) "
Celltrion Healthcare (Celltrion) has won tenders to supply infliximab to Singapore and rituximab to Thailand, while CCM Duopharma Biotech Bhd (CCMD) aims to increase revenue contribution from its biosimilar products from 22% to over 25%.
"
  ["description"]=>
  string(244) "
Celltrion Healthcare (Celltrion) has won tenders to supply infliximab to Singapore and rituximab to Thailand, while CCM Duopharma Biotech Bhd (CCMD) aims to increase revenue contribution from its biosimilar products from 22% to over 25%.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(134) "http://www.gabionline.net//Biosimilars/General/Celltrion-wins-biosimilar-deals-and-Duopharma-increases-focus-on-biosimilars-in-SE-Asia"
  ["blog_url"]=>
  string(134) "http://www.gabionline.net//Biosimilars/General/Celltrion-wins-biosimilar-deals-and-Duopharma-increases-focus-on-biosimilars-in-SE-Asia"
  [15]=>
  string(19) "2019-03-22 17:24:19"
  ["add_date"]=>
  string(19) "2019-03-22 17:24:19"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-03-25 16:03:40"
  ["create_at"]=>
  string(19) "2019-03-25 16:03:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1777"
  ["article_id"]=>
  string(4) "1777"
  [1]=>
  string(79) "FDA approves generics from Amneal and Dr Reddy’s, and Natco submits ANDA"
  ["article_title"]=>
  string(79) "FDA approves generics from Amneal and Dr Reddy’s, and Natco submits ANDA"
  [2]=>
  string(160) "In January 2019, the US Food and Drug Administration (FDA) approved Amneal Pharmaceutical’s (Amneal) generic Exelon patch and Dr Reddy’s Laborator"
  ["short_description"]=>
  string(160) "In January 2019, the US Food and Drug Administration (FDA) approved Amneal Pharmaceutical’s (Amneal) generic Exelon patch and Dr Reddy’s Laborator"
  [3]=>
  string(315) "
In January 2019, the US Food and Drug Administration (FDA) approved Amneal Pharmaceutical’s (Amneal) generic Exelon patch and Dr Reddy’s Laboratories (Dr Reddy’s) Tosymra nasal spray, and Natco Pharma submitted an abbreviated new drug application (ANDA) to FDA for its Ibrutinab tablets.
"
  ["description"]=>
  string(315) "
In January 2019, the US Food and Drug Administration (FDA) approved Amneal Pharmaceutical’s (Amneal) generic Exelon patch and Dr Reddy’s Laboratories (Dr Reddy’s) Tosymra nasal spray, and Natco Pharma submitted an abbreviated new drug application (ANDA) to FDA for its Ibrutinab tablets.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(112) "http://www.gabionline.net//Generics/News/FDA-approves-generics-from-Amneal-and-Dr-Reddy-s-and-Natco-submits-ANDA"
  ["blog_url"]=>
  string(112) "http://www.gabionline.net//Generics/News/FDA-approves-generics-from-Amneal-and-Dr-Reddy-s-and-Natco-submits-ANDA"
  [15]=>
  string(19) "2019-03-22 17:08:16"
  ["add_date"]=>
  string(19) "2019-03-22 17:08:16"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-03-25 16:03:40"
  ["create_at"]=>
  string(19) "2019-03-25 16:03:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2010"
  ["article_id"]=>
  string(4) "2010"
  [1]=>
  string(108) "Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease"
  ["article_title"]=>
  string(108) "Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease"
  [2]=>
  string(150) "CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discont"
  ["short_description"]=>
  string(150) "CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discont"
  [3]=>
  string(251) "CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of..."
  ["description"]=>
  string(251) "CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(278) "https://www.drugs.com/clinical_trials/biogen-eisai-discontinue-phase-3-engage-emerge-trials-aducanumab-alzheimer-s-18105.html?utm_source=ddc&utm_medium=rss&utm_campaign=Biogen+and+Eisai+to+Discontinue+Phase+3+ENGAGE+and+EMERGE+Trials+of+aducanumab+in+Alzheimer%E2%80%99s+Disease"
  ["blog_url"]=>
  string(278) "https://www.drugs.com/clinical_trials/biogen-eisai-discontinue-phase-3-engage-emerge-trials-aducanumab-alzheimer-s-18105.html?utm_source=ddc&utm_medium=rss&utm_campaign=Biogen+and+Eisai+to+Discontinue+Phase+3+ENGAGE+and+EMERGE+Trials+of+aducanumab+in+Alzheimer%E2%80%99s+Disease"
  [15]=>
  string(19) "2019-03-22 02:03:28"
  ["add_date"]=>
  string(19) "2019-03-22 02:03:28"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1979"
  ["article_id"]=>
  string(4) "1979"
  [1]=>
  string(78) "Cuts to preregistration pharmacy training: education chiefs slam the brakes on"
  ["article_title"]=>
  string(78) "Cuts to preregistration pharmacy training: education chiefs slam the brakes on"
  [2]=>
  string(152) "On 19 February 2019, Hazel Smith from Health Education England wrote to hospital chief pharmacists about cuts to funding for the training of hospital"
  ["short_description"]=>
  string(152) "On 19 February 2019, Hazel Smith from Health Education England wrote to hospital chief pharmacists about cuts to funding for the training of hospital"
  [3]=>
  string(214) "On 19 February 2019, Hazel Smith from Health Education England wrote to hospital chief pharmacists about cuts to funding for the training of hospital preregistration pharmacists for the second time in six weeks."
  ["description"]=>
  string(214) "On 19 February 2019, Hazel Smith from Health Education England wrote to hospital chief pharmacists about cuts to funding for the training of hospital preregistration pharmacists for the second time in six weeks."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "12"
  ["rss_id"]=>
  string(2) "12"
  [14]=>
  string(160) "https://www.pharmaceutical-journal.com/news-and-analysis/features/cuts-to-preregistration-pharmacy-training-education-chiefs-slam-the-brakes-on/20206297.article"
  ["blog_url"]=>
  string(160) "https://www.pharmaceutical-journal.com/news-and-analysis/features/cuts-to-preregistration-pharmacy-training-education-chiefs-slam-the-brakes-on/20206297.article"
  [15]=>
  string(19) "2019-03-21 22:00:00"
  ["add_date"]=>
  string(19) "2019-03-21 22:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:55"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:55"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}